Big news for mens health. The FDA is officially advancing 12 high demand peptides including BPC 157, GHK Cu, and TB500 toward the next phase this July clearing the path for broader access and renewed FDA Peptide Reclassification 2026: What It Means for Providers HIMS: Regulatory Arbitrage and the Future of Personalized Medicine FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law